PFCS
GRCE

Pale Fire Capital SE’s Grace Therapeutics GRCE Stock Holding History

Pale Fire Capital SE’s Portfolio GRCE Stock Details GRCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$175K Buy
+37,762
New +$148K 0.02% 58

Other funds holding GRCE

Cerity Partners
Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return

Pale Fire Capital SE's GRCE Position: Q1 2026 in Review

Pale Fire Capital SE opened a new position in Grace Therapeutics (GRCE) in Q1 2026: 37,762 shares worth $175K. The stake represents 0.02% of the portfolio and ranks #58 among its holdings.

34 funds tracked by Wall St. Rank hold GRCE as of Q1 2026.

  • Pale Fire Capital SE held 37,762 shares of Grace Therapeutics worth $175K as of Q1 2026.
  • Grace Therapeutics was a new Pale Fire Capital SE position in Q1 2026.
  • Grace Therapeutics made up 0.02% of Pale Fire Capital SE's portfolio in Q1 2026, its #58 holding.
  • 34 funds tracked by Wall St. Rank held Grace Therapeutics as of Q1 2026.

Based on Pale Fire Capital SE's 13F filing for Q1 2026, filed 14 May 2026.